Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The US market for neurovascular devices will grow strongly through 2027 as a result of the adoption of innovative devices as well as the ongoing expansion of dedicated infrastructure for neurovascular interventions.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for stroke devices in the US across a 10-year period
The results of the ASTER trial triggered the incorporation of aspiration thrombectomy into guidelines as a first-line treatment for AIS.
How will the updated guidelines impact market growth?
What barriers continue to affect uptake of aspiration thrombectomy?
How significantly are cost concerns impacting neurovascular thrombectomy device choice in the US market?
A number of companies are launching new neurovascular devices in the US market.
How strongly will competition increase in market segments that were previously monopolized by a single competitor?
What tactics are smaller companies using to gain share in the market?
How does the competitive landscape in the US differ from other global neurovascular device markets?
The initial results of the HEAT trial demonstrated the superiority of hydrogel-coated embolization coils in comparison to bare platinum coils.
How dramatically will these results impact the use of coated and bare platinum coils? What role will cost play in device uptake?
Which companies will benefit from these favorable results, and which companies will be negatively impacted?
Already a Client? Log in to access this report.
Yang Yun Li is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in clot management device markets. Yang holds a in Pharmaceutical Sciences from the University of Toronto.